Climb Bio Inc (CLYM)

08:05 AM

Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026 - markets.businessinsider.com

08:05 AM

07:00 AM

Climb Bio to share antibody trial data at European renal congress - Stock Titan

07:00 AM

May 23, 2026

Climb Bio Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentOpen Trading Community - Newser

May 23, 2026

May 22, 2026

Climb Bio teases key Budoprutug, CLYM116 readouts at BioConnect - MSN

May 22, 2026

May 21, 2026

Climb Bio Inc. (CLYM) Surges Over 3% – Approaching Key Resistance ZoneTrending Momentum Stocks - newser.com

May 21, 2026

May 21, 2026

Climb Bio, Inc. drives new focus on APRIL-targeted B cell therapies at Dallas workshop - Traders Union

May 21, 2026

May 21, 2026

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect - sharewise.com

May 21, 2026

May 21, 2026

Climb Bio, Inc.Common Stock (CLYM) Stock Price, News, Quote & History - FinancialContent

May 21, 2026

May 20, 2026

Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Climb Bio (CLYM) and Boston Scientific (BSX) - The Globe and Mail

May 20, 2026

May 20, 2026

Climb Bio (CLYM) Stock Price, News & Analysis - MarketBeat

May 20, 2026

May 20, 2026

Raymond James Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo

May 20, 2026

May 19, 2026

Piper Sandler reiterates Climb Bio stock rating on IgAN opportunity By Investing.com - Investing.com Nigeria

May 19, 2026

May 19, 2026

Climb Bio, Inc. participates in HC Wainwright fireside chat to outline strategic direction - Traders Union

May 19, 2026

May 19, 2026

CLYM: Multiple clinical data readouts in 2024 will shape pivotal study plans and market positioning - TradingView

May 19, 2026

May 19, 2026

Piper Sandler reiterates Climb Bio stock rating on IgAN opportunity - Investing.com

May 19, 2026

May 19, 2026

Piper Sandler Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $23 - Moomoo

May 19, 2026

May 18, 2026

Climb Bio (CLYM) price target increased by 18.34% to 19.62 - MSN

May 18, 2026

May 17, 2026

Climb Bio (CLYM) Q1 2026 Earnings: Why the Beat MattersFree Market Insights - Newser

May 17, 2026

May 16, 2026

Number of shareholders of Climb Bio, Inc. – NASDAQ:CLYM - TradingView

May 16, 2026

May 14, 2026

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress - The Manila Times

May 14, 2026

May 14, 2026

Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 ... - Caledonian Record

May 14, 2026

May 14, 2026

New immune thrombocytopenia antibody data headed to EHA 2026 - Stock Titan

May 14, 2026

May 12, 2026

H.C. Wainwright raises Climb Bio stock price target on trial progress - Investing.com Nigeria

May 12, 2026

May 12, 2026

Climb Bio to Present at Upcoming Investor Conferences - markets.businessinsider.com

May 12, 2026

May 12, 2026

H.C. Wainwright Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $20 - Moomoo

May 12, 2026

May 12, 2026

H.C. Wainwright raises Climb Bio stock price target on trial progress By Investing.com - Investing.com South Africa

May 12, 2026

May 12, 2026

Biotech Climb Bio plans May and June investor talks online - Stock Titan

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 11, 2026

Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN

May 11, 2026

May 09, 2026

Climb Bio (NASDAQ:CLYM) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat

May 09, 2026

May 08, 2026

Wedbush Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $17 - Moomoo

May 08, 2026

May 08, 2026

Budo judo moves aplenty for Climb in autoimmune - BioWorld News

May 08, 2026

May 07, 2026

Baird Maintains Climb Bio(CLYM.US) With Buy Rating, Raises Target Price to $21 - Moomoo

May 07, 2026

May 07, 2026

Climb Bio, Inc. 1Q 2026: Net income $(13.7M), EPS $(0.20) — 10-Q Summary - TradingView

May 07, 2026

May 07, 2026

Climb Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 07, 2026

May 07, 2026

Climb Bio (NASDAQ: CLYM) trims Q1 2026 loss and raises $110M to fund pipeline - Stock Titan

May 07, 2026

May 07, 2026

[8-K] Climb Bio, Inc. Reports Material Event - Stock Titan

May 07, 2026

May 07, 2026

$110M financing gives Climb Bio room for multiple 2026 drug data readouts - Stock Titan

May 07, 2026

May 07, 2026

Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com

May 07, 2026

May 07, 2026

A Quick Look at Today's Ratings for Climb Bio(CLYM.US), With a Forecast Between $19 to $22 - Moomoo

May 07, 2026

May 06, 2026

Wedbush Adjusts Price Target on Climb Bio to $15 From $14, Maintains Outperform Rating - Moomoo

May 06, 2026

May 06, 2026

Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating - Moomoo

May 06, 2026

May 05, 2026

Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE - Yahoo Finance

May 05, 2026

May 05, 2026

Climb Bio Secures 110 Million Dollars Through Private Stock Placement - HarianBasis.co

May 05, 2026

May 05, 2026

Climb Bio reports B-cell depletion data for budoprutug trial By Investing.com - Investing.com South Africa

May 05, 2026

May 05, 2026

Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing - Insider Monkey

May 05, 2026